Pharmacokinetic/pharmacodynamic (PK/PD) relationships for the angiogenesis inhibitor ABT-510 in preclinical efficacy models

被引：0
|
作者：
Carr, R
Marsh, K
Schneider, A
Henkin, J
Wang, Y
Joseph, I
Khanna, C
Humerickhouse, R
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 2002年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
250
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [41] Pharmacokinetic/Pharmacodynamic (PK/PD) relationships for novel HDAC inhibitors in a mouse xenograft HCT116 tumor model
    Jayaraman, Ramesh
    Pasha, Mohammed Khalid
    Yeo, Pauline
    Sangthongpitag, Kanda
    Wang, Haishan
    Hentze, Hannes
    Diermayr, Veronica
    Wood, Jeanette
    Ethirajulu, Kantharaj
    CANCER RESEARCH, 2009, 69
  • [42] POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING AND SIMULATION FOR TIGULIXOSTAT, A NOVEL XANTHINE OXIDASE INHIBITOR FOR THE TREATMENT OF GOUT WITH HYPERURICEMIA
    Denney, W.
    Lee, M.
    Lee, N.
    Jun, H.
    Seo, J.
    Lee, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S69 - S69
  • [43] Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of BACE Inhibitor LY2886721 in Healthy Volunteers (HVs) at Steady State
    Martenyi, Ferenc
    Willis, Brian
    Dean, Robert
    Gonzales, Celedon
    Komjathy, Stephen
    Monk, Scott
    Lowe, Stephen
    Daugherty, Leslie
    Nakano, Masako
    Mergott, Dustin
    May, Patrick
    NEUROLOGY, 2013, 80
  • [44] A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models
    Singh, Dharaminder
    Deosarkar, Sudhir P.
    Cadogan, Elaine
    Flemington, Vikki
    Bray, Alysha
    Zhang, Jingwen
    Reiserer, Ronald S.
    Schaffer, David K.
    Gerken, Gregory B.
    Britt, Clayton M.
    Werner, Erik M.
    Gibbons, Francis D.
    Kostrzewski, Tomasz
    Chambers, Christopher E.
    Davies, Emma J.
    Montoya, Antonio Ramos
    Fok, Jacqueline H. L.
    Hughes, David
    Fabre, Kristin
    Wagoner, Matthew P.
    Wikswo, John P.
    Scott, Clay W.
    PLOS BIOLOGY, 2022, 20 (05)
  • [45] Preclinical PK/PD/Efficacy relationship of MLN8054, a small molecule Aurora A kinase inhibitor
    Huck, Jessica
    Chakravarty, Arijit
    Yu, Li
    Zhang, Mengkun
    Burke, Kristine
    Kim, Mi-Sook
    Stringer, Bradley
    Sells, Todd
    Claiborne, Christopher
    Manfred, Mark
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3589S - 3590S
  • [46] Preclinical pharmacokinetic/pharmacodynamic (PK/PD) relationship demonstrated for BVD-723, a potent and selective phosphoinositide 3-kinase gamma (PI3Ky) inhibitor
    Knoerzer, Deborah
    Teresk, Martin
    Krutzik, Peter
    O'Donnell, Erika
    DeCrescenzo, Gary
    Welsch, Dean
    Emery, Caroline
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [47] A new graphical tool for global evaluation of population pharmacokinetic and/or pharmacodynamic (PK/PD) models: the Visual Predictive Extended Residuals
    Khachman, D.
    Laffont, C.
    Concordet, D.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 2 - 2
  • [48] Pharmacodynamic-pharmacokinetic (PD/PK) profile of the phosphodiesterase (PDE)4 inhibitor, V11294A, in human volunteers.
    Gale, DD
    Landells, LJ
    Spina, D
    Miller, AJ
    Smith, K
    Nichols, T
    Rotshteyn, Y
    Tonelli, F
    Lacouture, P
    Burch, RM
    Page, CP
    O'Conner, BJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A108 - A108
  • [49] A Phase I Dose-escalation, Pharmacokinetic (PK) and Pharmacodynamic (PD) Evaluation of LY2940680, an Oral Smo Inhibitor
    Bendell, J.
    Weiss, G.
    Infante, J.
    Ramanathan, R.
    Jones, S.
    Korn, R.
    Burns, H.
    Brail, L.
    Jones, E.
    Von Hoff, D.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 182 - 182
  • [50] Lack of pharmacokinetic (PK) and pharmacodynamic (PD) interaction between the first synthetic factor Xa inhibitor and warfarin in human volunteers.
    Faaij, RA
    Burggraaf, J
    Cohen, AF
    BLOOD, 2000, 96 (11) : 56A - 56A
12345